Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Compendia

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

E-News

Print Subscription

BIOSIMILAR APPROVALS

Articles

Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.

HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain

Denise Myshko is your editorial contact for the Formulary Watch. She joined Formulary Watch as editor is June 2021 from Oncology Live. Prior to that, she was managing editor of PharmaVOICE, a trade publication in the pharmaceutical industry. Email: dmyshko@mjhlifesciences.com

As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.

CVS Caremark Switches Up Biosimilar Coverage in 2024

Videos

Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, explains the purpose of dual-pricing strategies for adalimumab biosimilars and predicts whether these strategies will occur in other treatment spaces.

Dr Chelsee Jensen Discusses Pricing Strategies for Adalimumab Biosimilars

A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.

Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim

Tommy Pourmahram

Articles